Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company's lead product candidate is nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, which is in Phase 2 clinical trial. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Skye Bioscience Inc.

In a dramatic turn of events, Skye Bioscience, Inc. finds itself at the center of a class action lawsuit, accused of misleading investors about the...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SKYE	$1.09	-5.22%	362.67K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SKYE	$1.09	-5.2%	362.67K
3
4
5
6

SKYE

SKYE

No Data Available

Get Skye Bioscience Inc. Data in Excel

Get Skye Bioscience Inc. Data in Excel